Saturday, November 21, 2026

mounjaro blindness risk

Mounjaro (tirzepatide) carries a potential, rare risk of sudden vision loss linked to a serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION). In November 2026, the U.S. Food and Drug Administration (FDA) required all GLP-1 receptor agonist medications—including Mounjaro—to add warnings about this potential risk to their safety labels. [1, 2, 3]

What the Risk Actually Means
  • Rarity: NAION is rare, and the overall added risk appears small. A direct cause-and-effect link has not been proven, and people taking GLP-1 drugs for diabetes or obesity often have baseline risk factors for optic nerve issues. [1, 2, 3, 4]
  • How NAION Happens: It occurs when blood flow to the front of the optic nerve is reduced or blocked, potentially causing sudden, painless vision loss—usually in one eye—that can be permanent. [1, 2]
  • Other Vision Changes: Mild, temporary blurry vision or dry eyes can also happen, especially while blood sugar levels shift or fluid intake changes. Rapid blood sugar improvements can also temporarily worsen existing diabetic retinopathy. [1, 2]
Symptoms That Need Urgent Care
Seek immediate medical or eye care if you notice: [1, 2, 3]
  • Sudden, painless vision loss in one eye (including upon waking) [1]
  • Blind spots, tunnel vision, or a shadow/curtain in your field of view [1, 2]
  • Blurred or hazy central vision, or color changes [1]
Do not stop taking Mounjaro without talking to your prescribing doctor first. For more details on the regulatory update, see coverage from BBC News and The Guardian. [1, 2, 3]